)
Visual
test
Aroa Biosurgery
Aroa Biosurgery (ARX) investor relations material
Aroa Biosurgery Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary2 Feb, 2026
Executive summary
Strong clinical and commercial momentum for Myriad, with positive trauma study results and expanding evidence base, including rapid tissue coverage and low complication rates in trauma procedures.
Symphony positioned for growth with US CMS setting a single reimbursement rate of US$127.14/cm² for outpatient skin substitutes, supporting broader adoption and commercial strategy focused on hospital outpatient departments and multiple care settings.
Largest ongoing multicenter study (MASTRR) for bioscaffolds in complex reconstruction with 450 patients enrolled; trauma subgroup shows strong clinical outcomes and reduced complications.
Guidance for FY26 revenue and EBITDA tracking toward the upper end of the range, with ongoing profitability and cash flow positivity.
Momentum driven by Myriad's success in soft tissue reconstruction, accumulating clinical evidence, and continued contribution from TELA Bio.
Financial highlights
FY26 total revenue guidance: NZ$92–100 million (constant currency), representing 10–20% year-over-year growth; normalized EBITDA: NZ$5–8 million.
Myriad product expected to deliver over 25% year-over-year constant currency growth.
Actual sales and EBITDA are tracking toward the upper end of guidance.
Cash flow positive for the last four quarters and expected for the full year.
Strong Q3 performance driven by direct sales and stable Ovitex sales.
Outlook and guidance
FY26 results expected at the upper end of guidance due to sales momentum and favorable US reimbursement changes.
Symphony RCT results expected by fiscal year-end or by end of March 2026, with publication expected in FY27.
Guidance assumes stable US tariff rates, no material decline in US medical procedures, and no major disruptions to manufacturing or transport.
Symphony anticipated to match or exceed Myriad's previous growth trajectory, depending on market and reimbursement dynamics.
Guidance based on NZ$/US$ exchange rate of 0.60.
Symphony's market share gain strategy
Myriad trauma study's sales conversion impact
Key drivers for increasing profitability?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- BPT
H1 FY26 revenue hit $1B, with strong gas prices and LNG cargoes offsetting lower production. - CPAY
Record 2025 results and 2026 outlook driven by strong segment growth and capital deployment. - 032640
Net income surged 61.9% year-over-year, with strong wireless and enterprise growth. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue. - COHR
Q2 FY26 revenue up 17% to $1.69B, with strong EPS growth and robust datacenter demand. - ALGT
Q4 2025 saw record results and margin growth, with 2026 outlook boosted by Sun Country deal. - STC
Record bookings, strong cash flow, and margin expansion drive improved outlook.
Aroa Biosurgery
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aroa Biosurgery Limited develops and manufactures regenerative tissue repair products derived from extracellular matrix biomaterials. The company’s products are used in wound care, soft tissue reconstruction, and surgical applications. Aroa Biosurgery serves healthcare providers and medical institutions across international markets. The company is headquartered in Auckland, New Zealand, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage